The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Prevention of Bacterial Infection in Neutropenic Patients with Hematologic Malignancies: A Randomized, Multicenter Trial Comparing Norfloxacin with Ciprofloxacin

[+] Article, Author, and Disclosure Information

Grant Support: In part by Bayer Italia, which also provided ciprofloxacin.

Requests for Reprints: Albano Del Favero, MD, Istituto Clinica Medica 1, Universita' di Perugia, Policlinico Monteluce, 06100 Perugia, Italy.

© 1991 American College of PhysiciansAmerican College of Physicians

Ann Intern Med. 1991;115(1):7-12. doi:10.7326/0003-4819-115-1-7
Text Size: A A A

Objective: To compare the efficacy of norfloxacin and ciprofloxacin in preventing bacterial infection in neutropenic patients.

Design: A randomized, controlled, multicenter trial.

Setting: Twenty-one hematologic units in tertiary care or university hospitals.

Patients: Eight hundred and one consecutive, afebrile, adult patients who had hematologic malignancies or who had bone marrow transplantation and chemotherapy-induced neutropenia (neutrophil count, < 1000/mm3) expected to last more than 10 days.

Intervention: Patients were randomly assigned to receive orally every 12 hours norfloxacin, 400 mg, or ciprofloxacin, 500 mg.

Measurements: Efficacy analysis was done for 619 patients: 319 treated with norfloxacin and 300 treated with ciprofloxacin.

Main Results: More patients receiving ciprofloxacin did not develop fever during neutropenia and did not receive antibiotics (34%) compared with those receiving norfloxacin (25%) (P = 0.01). Patients receiving ciprofloxacin had a lower rate of microbiologically documented infection (17% compared with 24%; P = 0.058), particularly of infection from gram-negative bacilli (4% compared with 9%; P = 0.03). The interval to the first febrile episode was also longer in patients receiving ciprofloxacin (8.3 compared with 7.2 days; P = 0.055). The rates of clinically documented infection, fever of unknown origin, and mortality as well as compliance and tolerability were similar in the two groups. Patients who had neutropenia for less than 15 days, who had severe neutropenia for less than 7 days, and who received antifungal prophylaxis benefited most from ciprofloxacin therapy.

Conclusion: Ciprofloxacin should be used to prevent the development of infection in neutropenic patients with hematologic malignancies.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.